A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
NCT ID: NCT05389319
Last Updated: 2025-03-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
PHASE1
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-24
Study Completion Date
2028-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV\_Beta in healthy participants who had received the full course of vaccination, including booster vaccination (i.e., having received 3 doses) with the Pfizer/BioNTech-BNT162b2 vaccine (Comirnaty).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
NCT04955626
SARS-CoV-2 Infection
COVID-19
COMPLETED
PHASE3
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861
SARS-CoV-2 Infection
COVID-19
COMPLETED
PHASE1
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
NCT04713553
SARS-CoV-2 Infection
COVID-19
COMPLETED
PHASE3
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
NCT04927065
SARS-CoV-2
COMPLETED
PHASE2/PHASE3
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290
SARS-CoV-2 Infection
COVID-19
COMPLETED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants will undergo baseline assessments and will receive 1 injection of Prime-2-CoV\_Beta at Day 1. Participants will be followed up through 6 months post-booster vaccination. Follow-up visits will be performed at Days 4, 8, 15, 29, and Months 3 and 6, to assess the safety, tolerability, and immunogenicity of Prime-2-CoV\_Beta. Additional safety and tolerability data will be assessed 1 day and 2 days after booster vaccination (Days 2 and 3) by telephone. A total of 60 participants is planned to be vaccinated in 5 cohorts of 12 participants each. Dose ranging of Prime-2-CoV\_Beta will be done by dose escalation with doses ranging from 3x10000 plaque forming units (PFUs) up to 3x10 000 000 PFUs
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
COVID-19
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Cohorts 1 to 5 will include a safety lead with 1 sentinel participant. If no safety issues occurred within the on-site monitoring period as assessed by the investigator and solicited during telephone visits, the next 2 participants in that dose cohort will be vaccinated. After an 48-hour observation period and assuming no safety issues were identified in these 2 participants, an additional 4 participants will be vaccinated. After a 48-hour observation period, and assuming that no safety problems were noted in these 4 participants, the remaining participants in the dosing group will be vaccinated. Each participant will be observed for at least 4 hours at the study center after Prime-2-CoV\_Beta booster vaccination. After the last participant of each of the Cohorts 1 to 4 has completed 7 days of follow up after the Prime-2-CoV\_Beta booster vaccination, all safety data will be reviewed by the safety review committee.
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Prime-2-CoV\_Beta, dose: 30 000 PFUs
Group Type
EXPERIMENTAL
Prime-2-CoV_Beta
Intervention Type
BIOLOGICAL
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Cohort 2
Prime-2-CoV\_Beta, dose: 300 000 PFUs
Group Type
EXPERIMENTAL
Prime-2-CoV_Beta
Intervention Type
BIOLOGICAL
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Cohort 3
Prime-2-CoV\_Beta, dose: 3 000 000 PFUs
Group Type
EXPERIMENTAL
Prime-2-CoV_Beta
Intervention Type
BIOLOGICAL
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Cohort 4
Prime-2-CoV\_Beta, dose: 150 000 000 PFUs
Group Type
EXPERIMENTAL
Prime-2-CoV_Beta
Intervention Type
BIOLOGICAL
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Cohort 5
Prime-2-CoV\_Beta, dose: 30 000 000 PFUs
Group Type
EXPERIMENTAL
Prime-2-CoV_Beta
Intervention Type
BIOLOGICAL
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prime-2-CoV_Beta
1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Healthy adult men or women aged 18 to 55 years
2. Full course of vaccination, including booster vaccination (i.e., having received 3 doses) with Comirnaty, with the booster dose being administered at least 10 weeks before Day 1 as documented in a respective vaccination certificate
3. Able to understand the participant information and providing written informed consent
4. Body mass index of 18.5 to 30.0 kg/m² and weight \> 50 kg at Screening
5. Women of childbearing potential must:
1. have a negative pregnancy test at Screening (blood) and at Day 1 (urine)
2. agree to use, and be able to comply with, highly effective measures of contraception without interruption, from 14 days before Prime-2-CoV\_Beta booster vaccination until the end of the study.
A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) for this study: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only acceptable as true abstinence when this is in line with the preferred and usual lifestyle of the participant (abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal\] are not acceptable methods of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile women (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.
6. Male participants must agree not to intend to father a child or to donate sperm starting at Screening, throughout the clinical study. Male participants must also
1. abstain from sexual intercourse with a female partner (acceptable only if it is the participant's usual form of birth control/lifestyle choice: abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant or
2. use adequate barrier contraception (male condom) during treatment with the investigational product until the end of the study, and
3. ensure that, if they have a female partner of childbearing potential, the partner uses a highly effective contraceptive method as outlined in inclusion criterion number 5
4. use condoms during the entire study if they have a pregnant partner, to avoid exposure of the fetus to the investigational product
7. Willing and able to comply with all study procedures based on the investigator's judgment
2. Full course of vaccination, including booster vaccination (i.e., having received 3 doses) with Comirnaty, with the booster dose being administered at least 10 weeks before Day 1 as documented in a respective vaccination certificate
3. Able to understand the participant information and providing written informed consent
4. Body mass index of 18.5 to 30.0 kg/m² and weight \> 50 kg at Screening
5. Women of childbearing potential must:
1. have a negative pregnancy test at Screening (blood) and at Day 1 (urine)
2. agree to use, and be able to comply with, highly effective measures of contraception without interruption, from 14 days before Prime-2-CoV\_Beta booster vaccination until the end of the study.
A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) for this study: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only acceptable as true abstinence when this is in line with the preferred and usual lifestyle of the participant (abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal\] are not acceptable methods of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile women (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.
6. Male participants must agree not to intend to father a child or to donate sperm starting at Screening, throughout the clinical study. Male participants must also
1. abstain from sexual intercourse with a female partner (acceptable only if it is the participant's usual form of birth control/lifestyle choice: abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant or
2. use adequate barrier contraception (male condom) during treatment with the investigational product until the end of the study, and
3. ensure that, if they have a female partner of childbearing potential, the partner uses a highly effective contraceptive method as outlined in inclusion criterion number 5
4. use condoms during the entire study if they have a pregnant partner, to avoid exposure of the fetus to the investigational product
7. Willing and able to comply with all study procedures based on the investigator's judgment
Exclusion Criteria
Previous and concomitant therapy:
1. Receipt of any vaccine (licensed or investigational) from 4 weeks before Prime-2-CoV\_Beta booster vaccination or anticipated vaccination during the study until 6 weeks after the Prime-2-CoV\_Beta booster vaccination
2. Previous vaccination against COVID-19 with vaccines (licensed or investigational) other than Comirnaty
3. Current or previous treatment with another investigational drug and/or medical device (within 30 days of enrollment or 5 half-lives of that investigational drug)
4. Administration of immunoglobulins or any blood products within 2 months of Prime-2-CoV\_Beta booster vaccination
5. Chronic administration of medication associated with impaired immune responsiveness as judged by the investigator (including, but not limited to: immunosuppressive therapy, systemic corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy shots for hypo-sensitization, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs) within 2 months before the Prime-2-CoV\_Beta booster vaccination (Day 1). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
Previous and concomitant medical condition:
6. Active SARS-CoV-2 infection, confirmed by a commercially available SARS-CoV-2 rapid antigen test at Day 1, or currently on quarantine
7. Confirmed (by real-time quantitative polymerase chain reaction) SARS-CoV-2 infection after 2nd vaccination with Comirnaty
8. Known history of severe adverse reactions to any vaccine and/or severe allergic reactions to any component of the study vaccine, to any drug, or to any other exposure
9. Known history of angioedema
10. Pregnant or lactating women
11. Any confirmed or suspected immunosuppressive or immunodeficient condition
12. Known history of Guillain-Barré Syndrome
13. Known infection with human immunodeficiency virus, hepatitis C virus or hepatitis B virus
14. Active cancer (malignancy) within 5 years before Day 1 (except for adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
15. Moderate or severe illness and/or fever \> 38.0 °C within 1 week before Prime-2-CoV\_Beta booster vaccination
16. Any clinically significant health problem (medical history and physical examination) or clinically significantly abnormal finding in biochemistry and/or hematology blood tests, urinalysis, or electrocardiogram at Screening according to the investigator's opinion
17. Current or history of cardiovascular disease or structural cardiac disease (including chronic or congenital heart conditions, such as chronic hypertension, coronary heart disease, myocardial infarction and arrhythmias, hypertrophic cardiomyopathy, as well as a history of myocarditis after mRNA vaccinations)
18. History of mRNA vaccination-associated adverse events that were in nature and severity beyond the common AEs expected
19. Current or history of gastrointestinal disease, liver disease, renal disease or endocrine disorders, (including diabetes) and neurological illness (excluding migraine), when judged as clinically significant according to the investigator's opinion
20. Current or history of chronic respiratory diseases, including mild asthma treated by on-demand medication (resolved childhood asthma is allowed)
21. Current or history of alcohol and/or drug abuse within the last 6 months before Day 1
Previous and concomitant clinical study experience
22. Current participation in another study or previous enrollment in this clinical study
23. Investigator or employee of the study group or sponsor with direct involvement in the proposed study or relatives of the research staff with direct involvement in the proposed study
24. Prolonged exposure to sheep or goats (e.g., shepherds, sheep farmer)
1. Receipt of any vaccine (licensed or investigational) from 4 weeks before Prime-2-CoV\_Beta booster vaccination or anticipated vaccination during the study until 6 weeks after the Prime-2-CoV\_Beta booster vaccination
2. Previous vaccination against COVID-19 with vaccines (licensed or investigational) other than Comirnaty
3. Current or previous treatment with another investigational drug and/or medical device (within 30 days of enrollment or 5 half-lives of that investigational drug)
4. Administration of immunoglobulins or any blood products within 2 months of Prime-2-CoV\_Beta booster vaccination
5. Chronic administration of medication associated with impaired immune responsiveness as judged by the investigator (including, but not limited to: immunosuppressive therapy, systemic corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy shots for hypo-sensitization, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs) within 2 months before the Prime-2-CoV\_Beta booster vaccination (Day 1). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
Previous and concomitant medical condition:
6. Active SARS-CoV-2 infection, confirmed by a commercially available SARS-CoV-2 rapid antigen test at Day 1, or currently on quarantine
7. Confirmed (by real-time quantitative polymerase chain reaction) SARS-CoV-2 infection after 2nd vaccination with Comirnaty
8. Known history of severe adverse reactions to any vaccine and/or severe allergic reactions to any component of the study vaccine, to any drug, or to any other exposure
9. Known history of angioedema
10. Pregnant or lactating women
11. Any confirmed or suspected immunosuppressive or immunodeficient condition
12. Known history of Guillain-Barré Syndrome
13. Known infection with human immunodeficiency virus, hepatitis C virus or hepatitis B virus
14. Active cancer (malignancy) within 5 years before Day 1 (except for adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
15. Moderate or severe illness and/or fever \> 38.0 °C within 1 week before Prime-2-CoV\_Beta booster vaccination
16. Any clinically significant health problem (medical history and physical examination) or clinically significantly abnormal finding in biochemistry and/or hematology blood tests, urinalysis, or electrocardiogram at Screening according to the investigator's opinion
17. Current or history of cardiovascular disease or structural cardiac disease (including chronic or congenital heart conditions, such as chronic hypertension, coronary heart disease, myocardial infarction and arrhythmias, hypertrophic cardiomyopathy, as well as a history of myocarditis after mRNA vaccinations)
18. History of mRNA vaccination-associated adverse events that were in nature and severity beyond the common AEs expected
19. Current or history of gastrointestinal disease, liver disease, renal disease or endocrine disorders, (including diabetes) and neurological illness (excluding migraine), when judged as clinically significant according to the investigator's opinion
20. Current or history of chronic respiratory diseases, including mild asthma treated by on-demand medication (resolved childhood asthma is allowed)
21. Current or history of alcohol and/or drug abuse within the last 6 months before Day 1
Previous and concomitant clinical study experience
22. Current participation in another study or previous enrollment in this clinical study
23. Investigator or employee of the study group or sponsor with direct involvement in the proposed study or relatives of the research staff with direct involvement in the proposed study
24. Prolonged exposure to sheep or goats (e.g., shepherds, sheep farmer)
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FGK Clinical Research GmbH
INDUSTRY
Sponsor Role
collaborator
VisMederi srl
INDUSTRY
Sponsor Role
collaborator
Staburo GmbH
INDUSTRY
Sponsor Role
collaborator
Viedoc Technologies AB
UNKNOWN
Sponsor Role
collaborator
University Hospital Tuebingen
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meral Esen, Dr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tübingen, Institute of Tropical Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tübingen, Institute of Tropical Medicine
Tübingen, Baden-Wurttemberg, Germany
Site Status
Bernhard-Nocht-Institut für Tropenmedizin
Hamburg, City state of Hamburg, Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Germany
References
Explore related publications, articles, or registry entries linked to this study.
Esen M, Fischer-Herr J, Gabor JJ, Gaile JM, Fleischmann WA, Smeenk GW, de Moraes RA, Belard S, Calle CL, Woldearegai TG, Egger-Adam D, Haug V, Metz C, Reguzova A, Loffler MW, Balode B, Matthies LC, Ramharter M, Amann R, Kremsner PG. First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster. Vaccines (Basel). 2024 Nov 18;12(11):1288. doi: 10.3390/vaccines12111288.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRiME2_21_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365
UNKNOWN
PHASE2/PHASE3
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
NCT05148962
COMPLETED
PHASE1
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097
COMPLETED
PHASE2
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
NCT05144139
COMPLETED
PHASE1/PHASE2
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
NCT05602961
WITHDRAWN
PHASE1/PHASE2
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
NCT05381350
COMPLETED
PHASE3
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
NCT04949490
COMPLETED
PHASE2
Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.
NCT05330871
UNKNOWN
PHASE2
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
NCT05137236
COMPLETED
PHASE2
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
NCT05995275
COMPLETED
PHASE1/PHASE2
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
NCT05664932
UNKNOWN
PHASE3
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
NCT05925127
COMPLETED
PHASE2/PHASE3
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
NCT05079217
UNKNOWN
PHASE4
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
NCT05975060
COMPLETED
PHASE2/PHASE3
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
NCT05239806
UNKNOWN
PHASE2
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
NCT05374954
UNKNOWN
PHASE3
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
NCT04999111
COMPLETED
PHASE2
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
NCT05239832
UNKNOWN
PHASE2
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine
NCT05542693
UNKNOWN
PHASE2
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
NCT05004181
COMPLETED
PHASE2
New Generation mRNA Booster Vaccine Against Emerging VOCs
NCT05580159
UNKNOWN
PHASE3
Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity
NCT05289206
UNKNOWN
NA
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
NCT04537949
COMPLETED
PHASE1/PHASE2
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
NCT05366296
WITHDRAWN
PHASE1